Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

Peter F. Wright; Ruth A. Karron; Robert B. Belshe; Juliette Thompson; James E. Crowe; Thomas G. Boyce; Lisa L. Halburnt; George W. Reed; Stephen S. Whitehead; Edwin L. Anderson; Alec E. Wittek; Roberta Casey; Maryna Eichelberger; Bhagvanji Thumar; Valerie B. Randolph; Stephen A. Udem; Robert M. Chanock; Brian R. Murphy

doi:10.1086/315859

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

Peter F. Wright, Ruth A. Karron, Robert B. Belshe, Juliette Thompson, James E. Crowe, Thomas G. Boyce, Lisa L. Halburnt, George W. Reed, Stephen S. Whitehead, Edwin L. Anderson, Alec E. Wittek, Roberta Casey, Maryna Eichelberger, Bhagvanji Thumar, Valerie B. Randolph, Stephen A. Udem, Robert M. Chanock, Brian R. Murphy

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

256 Scopus citations

Abstract

A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

Original language	English (US)
Pages (from-to)	1331-1342
Number of pages	12
Journal	Journal of Infectious Diseases
Volume	182
Issue number	5
DOIs	https://doi.org/10.1086/315859
State	Published - 2000

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1086/315859

Cite this

Wright, P. F., Karron, R. A., Belshe, R. B., Thompson, J., Crowe, J. E., Boyce, T. G., Halburnt, L. L., Reed, G. W., Whitehead, S. S., Anderson, E. L., Wittek, A. E., Casey, R., Eichelberger, M., Thumar, B., Randolph, V. B., Udem, S. A., Chanock, R. M., & Murphy, B. R. (2000). Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. Journal of Infectious Diseases, 182(5), 1331-1342. https://doi.org/10.1086/315859

Wright, PF, Karron, RA, Belshe, RB, Thompson, J, Crowe, JE, Boyce, TG, Halburnt, LL, Reed, GW, Whitehead, SS, Anderson, EL, Wittek, AE, Casey, R, Eichelberger, M, Thumar, B, Randolph, VB, Udem, SA, Chanock, RM & Murphy, BR 2000, 'Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy', Journal of Infectious Diseases, vol. 182, no. 5, pp. 1331-1342. https://doi.org/10.1086/315859

@article{fb3bc01cd0fa4ae0b9f1ab9a54ad80f0,

title = "Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy",

abstract = "A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.",

author = "Wright, {Peter F.} and Karron, {Ruth A.} and Belshe, {Robert B.} and Juliette Thompson and Crowe, {James E.} and Boyce, {Thomas G.} and Halburnt, {Lisa L.} and Reed, {George W.} and Whitehead, {Stephen S.} and Anderson, {Edwin L.} and Wittek, {Alec E.} and Roberta Casey and Maryna Eichelberger and Bhagvanji Thumar and Randolph, {Valerie B.} and Udem, {Stephen A.} and Chanock, {Robert M.} and Murphy, {Brian R.}",

year = "2000",

doi = "10.1086/315859",

language = "English (US)",

volume = "182",

pages = "1331--1342",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

AU - Wright, Peter F.

AU - Karron, Ruth A.

AU - Belshe, Robert B.

AU - Thompson, Juliette

AU - Crowe, James E.

AU - Boyce, Thomas G.

AU - Halburnt, Lisa L.

AU - Reed, George W.

AU - Whitehead, Stephen S.

AU - Anderson, Edwin L.

AU - Wittek, Alec E.

AU - Casey, Roberta

AU - Eichelberger, Maryna

AU - Thumar, Bhagvanji

AU - Randolph, Valerie B.

AU - Udem, Stephen A.

AU - Chanock, Robert M.

AU - Murphy, Brian R.

PY - 2000

Y1 - 2000

N2 - A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

AB - A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

UR - http://www.scopus.com/inward/record.url?scp=0033791293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033791293&partnerID=8YFLogxK

U2 - 10.1086/315859

DO - 10.1086/315859

M3 - Article

C2 - 11010838

AN - SCOPUS:0033791293

SN - 0022-1899

VL - 182

SP - 1331

EP - 1342

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this